Zydus Cadila expects to launch its DNA COVID-19 vaccine in the first quarter of fiscal 2022 but it already has more advance purchase orders than it can produce. Meanwhile, the Indian firm is confident of saroglitazar being approved for primary biliary cholangitis in the US, with the NCE also poised to become the largest contributor to India sales in three to five years.
While Zydus Cadila is expected to launch its COVID-19 vaccine in the first quarter of fiscal 2022, which begins on 1 April 2021, demand for ZyCoV-D has already outstripped its yet to be commissioned manufacturing capacity.
“A lot of emerging countries are ready to accept Phase II data and even give approvals, for some we will...